Safety and efficacy of in-hospital clopidogrel-to-prasugrel switching in patients with acute coronary syndrome. An analysis from the ‘real world’

Journal of Thrombosis and Thrombolysis

Volumn 39, Issue 4, 2015, Pages 499-507

  Almendro Delia, Manuel ^a   Blanco Ponce, Emilia ^a   Gomez Domínguez, Rocío ^a   Gonzalez Matos, Carlos ^a   Lobo Gonzalez, Manuel ^a   Caballero Garcia, Auxiliadora ^b   Hidalgo Urbano, Rafael ^a   Cruz Fernandez, Maria Jose ^a   Garcia Rubira, Juan C ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^b Empresa Pública de Emergencias Sanitarias EPES de Andalucía   (Spain)

Author keywords

Acute coronary syndromes; Bleeding; Prasugrel; Switching

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; P2RY12 PROTEIN, HUMAN; PRASUGREL; PURINERGIC P2Y12 RECEPTOR; TICLOPIDINE;

ACUTE CORONARY SYNDROME; AGED; ANALOGS AND DERIVATIVES; BLEEDING; BLOOD; CHEMICALLY INDUCED; DRUG SUBSTITUTION; FEMALE; HUMAN; MALE; MIDDLE AGED; SEX DIFFERENCE; THROMBOSIS; VERY ELDERLY;

ACUTE CORONARY SYNDROME; AGED; AGED, 80 AND OVER; ASPIRIN; DRUG SUBSTITUTION; FEMALE; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; PRASUGREL HYDROCHLORIDE; RECEPTORS, PURINERGIC P2Y12; SEX FACTORS; THROMBOSIS; TICLOPIDINE;

EID: 84939881412     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-014-1139-5     Document Type: Article

References (19)

1. Hamm CW, Bassand JP, Agewall S et al (2011) ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 32:2999–3054
2. Steg PG, James SK, Atar D et al (2012) ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 33:2569–2619
3. Wiviott SD, Braunwald E, McCabe CH et al (2007) Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357:2001–2015
4. Bueno H, Storey RF, Danchin N, et al (2012) Current regional differences in the use of antiplatelet drugs for the treatment of acute coronary syndromes: results from the EPICOR study. Eur Heart J 33(suppl. 1):311. Abstract
5. Marchini J, Morrow D, Resnic F et al (2010) An Algorithm for use of prasugrel (effient) in patients undergoing cardiac catheterization and percutaneous coronary intervention. Crit Pathw Cardiol 9:192–198
6. Alexopoulos D, Goudevenos JA, Xanthopoulou I et al (2013) Implementation of contemporary oral antiplatelet treatment guidelines in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a report from the GReek AntiPlatelet rEgistry (GRAPE). Int J Cardiol 168:5329–5335
7. Montalescot G, Sideris G, Cohen R et al (2010) Prasugrel compared with high-dose clopidogrel in acute coronary syndrome. The randomised, double-blind ACAPULCO study. Thromb Haemost 103:213–223
8. Angiolillo DJ, Saucedo JF, Deraad R et al (2010) Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: results of the SWAP (SWitching Anti Platelet) study. J Am Coll Cardiol 56:1017–1023
9. Roe MT, Armstrong PW, Fox KA et al (2013) (2013) Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med 368:188–189
10. Schiele F, Puymirat E, Lorgis L, et al (2012) Switch and non switch in P2Y12 inhibition: the real life use of clopidogrel and prasugrel in patients with acute myocardial infarction. Insights from the FAST MI 2010 registry. Eur Heart J 33(Suppl. 1):204. Abstract
11. Bagai A, Peterson ED, Honeycutt E, et al (2012) In-Hospital switching of ADP receptor inhibitors in myocardial infarction patients treated with percutaneous coronary intervention: Insights from the TRANSLATE-ACS Study. Circulation 126:A15573. Abstract
12. Parodi G, De Luca G, Bellandi B, et al (2014) Switching from clopidogrel to prasugrel in patients undergoing coronary stent implantation. J Thromb Thrombolysis. doi:10.1007/s11239-013-1040-7.[in press]
13. Chesebro JH, Knatterud G, Roberts R et al (1987) Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation 76:15–142
14. Sandhu A, Seth M, Dixon S et al (2013) Contemporary use of prasugrel in clinical practice: insights from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium. Circ Cardiovasc Qual Outcomes 6:293–298
15. Wiviott SD, Trenk D, Frelinger AL et al (2007) Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation 116:2923–2932
16. Loh JP, Pendyala LK, Kitabata H et al (2013) Safety of reloading prasugrel in addition to clopidogrel loading in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Am J Cardiol 111:841–845
17. Diodati JG, Saucedo JF, French JK et al (2013) Effect on platelet reactivity from a prasugrel loading dose after clopidogrel loading dose compared with a prasugrel loading dose alone: transferring from clopidogrel loading dose to prasugrel loading dose in acute coronary syndrome patients (TRIPLET): a randomized controlled trial. Circ Cardiovasc Interv 6:567–574
18. Fournier N, Toesca R, Bessereau J et al (2013) Ticagrelor or prasugrel for pre-hospital protocols in STEMI? Int J Cardiol 168:4566–4567
19. Alexopoulos D, Xanthopoulou I, Deftereos S et al (2014) In-hospital switching of oral P2Y12 inhibitor treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention: prevalence, predictors and short-term outcome. Am Heart J 167(1):68–76